[go: up one dir, main page]

WO2004074436A3 - Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer - Google Patents

Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer Download PDF

Info

Publication number
WO2004074436A3
WO2004074436A3 PCT/US2004/004060 US2004004060W WO2004074436A3 WO 2004074436 A3 WO2004074436 A3 WO 2004074436A3 US 2004004060 W US2004004060 W US 2004004060W WO 2004074436 A3 WO2004074436 A3 WO 2004074436A3
Authority
WO
WIPO (PCT)
Prior art keywords
colon
treatment
lung cancer
gpcr
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/004060
Other languages
French (fr)
Other versions
WO2004074436A2 (en
Inventor
Amy W Lasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of WO2004074436A2 publication Critical patent/WO2004074436A2/en
Anticipated expiration legal-status Critical
Publication of WO2004074436A3 publication Critical patent/WO2004074436A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides for the use of a protein, HG38, a polynucleotide encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of colon and lung cancer.
PCT/US2004/004060 2003-02-19 2004-02-11 Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer Ceased WO2004074436A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44895903P 2003-02-19 2003-02-19
US60/448,959 2003-02-19

Publications (2)

Publication Number Publication Date
WO2004074436A2 WO2004074436A2 (en) 2004-09-02
WO2004074436A3 true WO2004074436A3 (en) 2007-02-22

Family

ID=32908678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004060 Ceased WO2004074436A2 (en) 2003-02-19 2004-02-11 Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer

Country Status (1)

Country Link
WO (1) WO2004074436A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10339820A1 (en) * 2003-08-22 2005-03-17 Hinzmann, Bernd, Dr. Use of G-protein coupled receptor, GPR49, peptides, protein and nucleic acid, for diagnosis and prognosis of tumors, also in screening for therapeutic and diagnostic agents
ES2277785B1 (en) * 2005-12-21 2008-06-16 Oryzon Genomics, S.A. METHOD OF DIFFERENTIAL EXPRESSION ANALYSIS IN COLORECTAL CANCER.
JP5931336B2 (en) 2007-07-02 2016-06-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for treating and diagnosing cancer
CA2705509A1 (en) 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
WO2010016766A2 (en) * 2008-08-08 2010-02-11 Koninklijke Nederlandse Akademie Van Wetenschappen Antibodies recognizing endogenous human lgr5 and/or lgr6
CN106167526A (en) 2011-07-15 2016-11-30 昂考梅德药品有限公司 RSPO bonding agent and its application
CA2878868A1 (en) 2012-07-13 2014-01-16 Austin L. Gurney Rspo3 binding agents and uses thereof
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Also Published As

Publication number Publication date
WO2004074436A2 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
BE2021C505I2 (en)
WO2003057134A8 (en) Specific binding agents of human angiopoietin-2
WO2003101283A3 (en) Diagnostics markers for lung cancer
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
UA96139C2 (en) Anti-neuropilin-1 (nrp1) antibody
WO2004022580A3 (en) Bh3 peptides and method of use thereof
WO2008071418A3 (en) Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases
WO2006064453A3 (en) Targeting agents for molecular imaging
WO2003087831A3 (en) Proteins involved in breast cancer
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
WO2005116076A3 (en) Neoplasm-specific polypeptides and their uses
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2005028498A3 (en) Kid3 and kid3 antibodies that bind thereto
WO2007058896A3 (en) Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
WO2007035092A3 (en) Vhh for the diagnosis, prevention and treatment of diseases associated with protein aggregates
WO2004074436A3 (en) Methods of use of a gpcr in the diagnosis and treatment of colon and lung cancer
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2008103202A3 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
NO20054049D0 (en) Procedure for diagnosis and treatment.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase